// App-Quantinova.ai

262 : Secukinumab demonstrates rapid and sustained efficacy in ankylosing spondylitis patients with normal or elevated baseline C-reactive protein levels: pooled analysis of two Phase 3 studies

Researchers

Presenter

  • Nick Barkham

Principal Investigators

  • Jrgen Braun

  • Joachim Sieper

  • Robert Landew

  • Xenofon Baraliakos

  • Corinne Miceli-Richard

  • Erhard Quebe-Fehling

  • Brian Porter

  • Kunal Gandhi

  • Dsire van der Heijde

Medical Centers

  • Rheumatology, New Cross Hospital, Wolverhampton, UNITED KINGDOM

  • Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany

  • Department of Gastroenterology, Infection and Rheumatology, University Clinic Benjamin Franklin, Berlin, GERMANY

  • Faculty of Medicine, University of Amsterdam and Atrium Medical Center, Amsterdam, NETHERLANDS

  • Institut Pasteur, APHP Hôpital Cochin, Paris, FRANCE

  • Global Medical Affairs Biostatistics in Global Drug Development, Novartis Pharma AG, Basel, SWITZERLAND

  • Immunology and Dermatology Franchise, Novartis Pharma AG, East Hanover, NJ

  • Department of Rheumatology, Leiden University Medical Centre, Leiden, UK

Locations

  • United Kingdom

  • Germany

  • Netherlands

  • France

  • Switzerland

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Autoimmune (AI)

Disease

  • Ankylosing spondylitis

Biomarkers

  • C reactive protein

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved